Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program.

scientific article published on 5 February 2018

Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.2147/OPTH.S150957
P932PMC publication ID5804729
P698PubMed publication ID29440872

P50authorCatherine Creuzot-GarcherQ64866954
P2093author name stringMarc Labetoulle
Christophe Baudouin
Pierre-Jean Pisella
Dahlia Ismail
Mourad Amrane
Serge Doan
Beatrice Cochener-Lamard
P2860cites workTopical cyclosporine: are all indications justified?Q87154377
TFOS DEWS II Diagnostic Methodology reportQ38652978
TFOS DEWS II Epidemiology ReportQ38652994
TFOS DEWS II Definition and Classification Report.Q38665717
Correlation Between the Inflammatory Marker HLA-DR and Signs and Symptoms in Moderate to Severe Dry Eye DiseaseQ38816983
TFOS DEWS II Management and Therapy ReportQ39453364
Evaluation of topical cyclosporine for the treatment of dry eye diseaseQ44443222
Antiinflammatory therapy for dry eye.Q44763839
Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.Q53620228
A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye.Q54222666
Economic and Humanistic Burden of Dry Eye Disease in Europe, North America, and Asia: A Systematic Literature ReviewQ26770830
Associations between signs and symptoms of dry eye disease: a systematic reviewQ26781979
The pathophysiology, diagnosis, and treatment of dry eye diseaseQ28083825
Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndromeQ33592784
Safety and efficacy of cyclosporine in the treatment of chronic dry eye.Q33825538
Diagnosing the severity of dry eye: a clear and practical algorithmQ34092386
Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 yearsQ34443357
Grading Of Corneal and Conjunctival Staining in the Context of Other Dry Eye TestsQ35542950
Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorbQ35854966
Etiology, prevalence, and treatment of dry eye diseaseQ37288773
Treatment of dry eye disease by the non-ophthalmologistQ37317581
Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-upQ37471561
Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meetingQ38151227
P275copyright licenseCreative Commons Attribution-NonCommercial 3.0 UnportedQ18810331
P6216copyright statuscopyrightedQ50423863
P407language of work or nameEnglishQ1860
P921main subjectcyclosporineQ367700
eye diseaseQ3041498
P304page(s)289-299
P577publication date2018-02-05
P1433published inClinical OphthalmologyQ5133782
P1476titleTopical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program.
P478volume12

Search more.